SCHEDULE: Vanguard Group Discloses 7.89% Stake in Rocket Pharma

The Vanguard Group reported a 7.89% beneficial ownership stake in Rocket Pharmaceuticals Inc. as of December 31, 2025, alongside an internal realignment affecting future reporting.

Summary

• The Vanguard Group reported beneficial ownership of 8,544,423 shares of Rocket Pharmaceuticals Inc. common stock.
• This represents 7.89% of the class of securities.
• The Vanguard Group holds shared voting power over 596,350 shares and shared dispositive power over 8,544,423 shares.
• An internal realignment at The Vanguard Group, effective January 12, 2026, means it no longer performs portfolio management services or administers proxy voting.
• Certain subsidiaries or business divisions of Vanguard are expected to report beneficial ownership separately (on a disaggregated basis) in the future.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, primarily due to the continued significant institutional ownership by The Vanguard Group, which can instill investor confidence. The internal realignment at Vanguard is an administrative matter for the reporting entity and does not reflect on Rocket Pharmaceuticals' performance.

Positives

• A major institutional investor, The Vanguard Group, maintains a significant stake of 7.89% in Rocket Pharmaceuticals Inc., indicating continued confidence in the company.
• The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Future Outlook

The Vanguard Group anticipates that certain subsidiaries or business divisions will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on SEC Release No. 34-39538, following an internal realignment effective January 12, 2026. These subsidiaries will continue to pursue the same investment strategies.

Management Comments

• "I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

StockSavvy.ai notes that large institutional holdings, such as Vanguard's 7.89% stake in Rocket Pharmaceuticals, are common in the biotechnology sector, where long-term investment in promising therapies is typical. Such filings provide transparency into major ownership positions, which can influence investor sentiment and signal institutional confidence in a company's long-term prospects, especially for a growth-oriented biotech firm like Rocket Pharmaceuticals.

Comparison to Industry Standards

• StockSavvy.ai observes that a 7.89% stake by a major asset manager like Vanguard is a substantial institutional position, aligning with typical large-cap institutional ownership patterns. For instance, BlackRock often holds similar or larger stakes in companies across various sectors, reflecting passive index fund investments or active management strategies.
• Compared to other biotech companies, a significant institutional stake can be a positive signal, as it suggests that large funds see value in the company's pipeline or market position. For example, similar ownership percentages are often seen in companies like Moderna or BioNTech, where large funds hold positions due to their inclusion in major indices.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: The continued significant stake by a major institutional investor like Vanguard may provide a level of confidence and stability for existing shareholders. The shift to disaggregated reporting by Vanguard's subsidiaries will offer more granular transparency into specific fund holdings.

Next Steps

• The Vanguard Group's subsidiaries or business divisions are expected to report beneficial ownership separately in future filings.

Key Dates

Recommendation

A Schedule 13G filing primarily discloses beneficial ownership and does not provide sufficient operational or financial data to warrant a "buy" or "sell" recommendation. The continued significant stake by The Vanguard Group is a neutral to slightly positive signal, indicating ongoing institutional interest, but it does not present new information about Rocket Pharmaceuticals' business fundamentals or future prospects that would change an existing investment thesis. Therefore, a "hold" recommendation is appropriate, pending further fundamental analysis of the company's performance and outlook.

Keywords

Rocket Pharmaceuticals, Vanguard Group, Institutional Ownership, SEC Filing, Schedule 13G, Common Stock, Beneficial Ownership, Investment Management, Biotechnology